Evolus, Inc. announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The " extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra- strength 40U and two active controls, BOTOX 20U and Jeuveau 20U.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.77 USD | +0.51% | +0.60% | +11.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.78% | 737M | |
+34.00% | 704B | |
+29.29% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+13.79% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau